{"meshTags":["Middle Aged","Treatment Outcome","Staurosporine","Humans","Leukemia, Myeloid, Acute","Mutation","Aged","Survival Analysis","Adult","Congresses as Topic","Antineoplastic Agents","fms-Like Tyrosine Kinase 3","Clinical Trials as Topic"],"meshMinor":["Middle Aged","Treatment Outcome","Staurosporine","Humans","Leukemia, Myeloid, Acute","Mutation","Aged","Survival Analysis","Adult","Congresses as Topic","Antineoplastic Agents","fms-Like Tyrosine Kinase 3","Clinical Trials as Topic"],"genes":["FLT3","FLT3"],"publicationTypes":["News"],"abstract":"In a phase III clinical trial, previously untreated patients with acute myeloid leukemia and FLT3 mutations received either the FLT3 inhibitor midostaurin or a placebo during chemotherapy. Patients who received midostaurin had a 5-year survival rate of 50.9% compared with 43.9% for the placebo group, as well as remissions that lasted nearly a year longer. ","title":"Midostaurin + Chemo Ups AML Survival.","pubmedId":"26739883"}